Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
Professor Umberto Malapelle, Chair of the Predictive Molecular Pathology Laboratory at the Department of Public Health of the University Federico II of Naples, Italy and the Scientific Secretary of the International Society of Liquid Biopsy, championed the new applications to support his research on lung and other cancers.
"When I learned SOPHiA GENETICS was offering applications from MSK on the SOPHiA DDM™ platform, I was really interested in the evaluation of the performance of this test, in particular because I see SOPHiA GENETICS as true collaborators to help pave the way for the future of cancer research," said Professor Malapelle.
"Bringing best-in-class technology to global organizations is crucial to help advance better health care for all. We are proud to work with trailblazers like Professor Malapelle, who are utilizing our technology and the collective power of our network to make strides in the next wave of cancer care," said Ross Muken, President, SOPHiA GENETICS.
Of the thirty-seven institutions adopting MSK solutions, thirty-four have signed on to adopt MSK-ACCESS® powered with SOPHiA DDM™, just ten months after the Liquid Biopsy application's launch. The decentralized deployment of MSK-ACCESS® has enabled hospitals and labs across the globe to launch world-renowned Liquid Biopsy testing from within the walls of their own institution, providing patients with a less-invasive option for genomic testing. In many cases, this decentralized testing also results in lower costs and faster turnaround times, while also enabling institutions to retain control of their patients' data for research or other purposes.
Internationally recognized organizations adopting the application include: Heidelberg University Hospital in Germany; Biopticka Laboratory in the Czech Republic; Hospital del Mar and Hospital La Fe in Spain; University Hospital of Nice and Marseille Regional Hospital Center in France; and Jewish General Hospital in Canada.
The complementary solid tumor application, MSK-IMPACT® powered with SOPHiA DDM™, has also attracted significant interest from leading organizations across the globe, including: the Jiménez Díaz Foundation University Hospital in Spain; the Cyprus Institute of Neurology and Genetics in Cyprus; and Sofiva Genomics in Taiwan.
Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS partnered in 2023 with a vision to use the sophisticated technology of the SOPHiA DDM™ Platform to bring MSK's state-of-the-art cancer testing capabilities to precision medicine institutions worldwide. The two leaders launched the Liquid Biopsy test MSK-ACCESS® powered with SOPHiA DDM™ in April 2024. In October 2024, SOPHiA GENETICS announced a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™, aiming to increase the availability of this innovative Liquid Biopsy solution worldwide. In November 2024, SOPHiA GENETICS announced the launch of the complementary Solid Tumor test, MSK-IMPACT® powered with SOPHiA DDM™. These collaborations have the potential to transform cancer research as they enable healthcare providers to draw from a continuously evolving base of real-world data and gain insights from diverse populations while using best-in-class technology.
Join us on Tuesday, February 25, 2025, at 11:00 a.m. (11:00) EDT / 5:00 p.m. (17:00) CET for the Precision Oncology Showcase, a virtual webinar which will spotlight the transformative potential of decentralized, AI-driven technologies for the advancement of cancer care.
About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
Forward-Looking StatementsThis press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/leading-healthcare-institutions-adopt-msk-access-for-liquid-biopsy-testing-302383208.html
SOURCE SOPHiA GENETICS
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2025/24/c7219.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
This Growth Stock Is Up 100% in the Last Year, but Still Down 15% From All-Time Highs: Should You Buy Today?
Key Points Shopify is growing quickly as it expands its commerce tools around the globe. It keeps adding new tools for customers, such as cryptocurrency payments and artificial intelligence (AI). Even though the business is great, the stock trades at an expensive valuation. 10 stocks we like better than Shopify › Shopify (NASDAQ: SHOP) is still in the middle of its 2021 hangover, as shares are down 15% from all-time highs set during the COVID-19 pandemic stock market bubble. The stock is up over 100% in the last 12 months, but still has not eclipsed previous highs after going through a brutal drawdown in 2022. At the same time, business performance has been rock-solid if not stellar, as management keeps adding new commerce tools and attracting new businesses to join the platform. With Shopify stock still down from all-time highs, should you buy shares in 2025 for your portfolio? Here's what the numbers say. Steady global expansion As a software and payments provider for online businesses, Shopify has grown to dominate the North American market. Now, it is moving internationally. Last quarter, growth in payments volume for its European division was 42%, outpacing overall growth. The company has built up a best-in-class set of tools for entrepreneurs and businesses of all sizes to sell and process payments online. Last quarter, even Starbucks signed a deal with Shopify, which shows the capabilities of the platform for online shopping. Overall revenue grew 31% year over year in the quarter, with strong growth expected for the rest of the year. Profit margins remain strong, with free cash flow margins of 16% in the quarter. This combination of growth and profitability is impressive and the key reason why Shopify's stock has soared in the last 12 months. As more and more businesses sign up for Shopify's software tools and payment processing, the more growth Shopify will achieve. Add new features such as advertising and the Shop Pay application for consumers, and it looks like growth will continue for many years into the future. AI, crypto, and new products Shopify is embracing new technologies as a way to leverage more usage from its business customers. It now has two artificial intelligence (AI) services called Sidekick and Magic that help analyze trends for a business, create content, and marketing products. Providing more value for enterprises will help customers stay entrenched within the Shopify ecosystem, leading to revenue growth and pricing power. What's more, Shopify is now beginning to expand and accept more forms of payment, such as Circle's stablecoin USDC. This should help with cross-border transactions and make it easier for shoppers who want to pay in different ways on Shopify's e-commerce storefronts. It will not only help drive new payment growth (which directly translates to revenue for Shopify), but also adoption of shopping across borders. On the whole, Shopify is building a huge ecosystem of products for businesses trying to sell things online. Its breadth of tools is unmatched in the software world, which is why so many commerce companies are signing deals with them. Expect this growth to continue for many years, as long as product innovation remains top tier. Should you buy Shopify stock? Shopify is a fast-growing business, but that does not necessarily make the stock a buy. Total revenue was $10 billion over the last 12 months. Revenue growth is expected to be over 20% for the rest of 2025. At the same time, 20%-plus growth cannot continue forever, no matter what company you are. On a long-enough timeline, a growth rate significantly above global economic growth would mean absorbing the entire global economy, which is not going to happen (no matter how good Shopify's commerce tools are). Revenue growth will be strong for many years, but it will eventually slow for Shopify. If Shopify's revenue grows at an average rate of 15% for the next five years, it will reach $20 billion in revenue by 2030. With a gross profit margin of 50%, I believe that Shopify can achieve a 20% net income margin once the business matures. This would turn $20 billion in revenue into $4 billion in annual net earnings five years from now. Today, Shopify has a market cap of $187 billion, which would give the stock a forward price-to-earnings ratio (P/E) of 47 based on these earnings growth projections. Despite how good of a business it is, this nosebleed P/E ratio means investors should avoid Shopify stock after its recent 100% run over the last 12 months. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify and Starbucks. The Motley Fool has a disclosure policy. This Growth Stock Is Up 100% in the Last Year, but Still Down 15% From All-Time Highs: Should You Buy Today? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29 minutes ago
- Business Wire
MediaCo's EstrellaTV Caps Off July With Surging Prime Ratings and Strong Year-Over-Year Growth Among P18-49
NEW YORK--(BUSINESS WIRE)--EstrellaTV, the multiplatform Spanish-language network owned by MediaCo Holding Inc. (Nasdaq: MDIA), closed out the July ratings period with significant momentum, notching some of its strongest audience gains of the season and extending a months-long trend of year-over-year growth in prime among Adults 18-49. In the final week of July, EstrellaTV delivered 18.3k among P18-49 viewers in Monday-Sunday prime, marking the network's 5th highest weekly prime delivery this season and a substantial +24% increase over its season-to-date average. This robust performance capped a month in which EstrellaTV averaged 13.8k P18-49 viewers in the daypart, up +13% vs. July 2024 (12.2k). It was the fourth consecutive month and the sixth time in the past eight months that EstrellaTV has posted year-over-year gains in this key demo. By contrast, top Spanish-language networks Univision and Telemundo posted year-over-year declines in July among P18-49 in MS prime of -35% and -21%, respectively. Unimas saw a +15% bump year-over-year for July, largely driven by FIFA Mundial coverage. However, without the heavy soccer content in the final week, Unimas' audience fell -43% compared to its average across the first three weeks of the month. Strong prime time programming fueled EstrellaTV's July performance: Alarma TV (9p) averaged 30.4k P18-49 viewers in July, up +37% vs. its season-to-date average. In the final two weeks of the month, the show soared even higher, averaging 38.1k and 35.7k, respectively. Tengo Talento, Mucho Talento (8p) closed the month strong, delivering 18.7k P18-49 viewers in the final week, +10% above its STD average. 100 Latinos Dijeron (7p) was also a standout, climbing +23% vs. STD in the final week (18.7k vs. 15.2k). These gains reinforce EstrellaTV's growing relevance among younger Hispanic audiences and the continued strength of its programming strategy. MediaCo's EstrellaTV added more firepower to its summer season with the live music, reality competition, Objetivo Fama, on August 2nd at 8PM EST. Since its premiere, the show is building momentum with viewers and part of a non-stop music and soccer programming line-up this Saturday, August 16 th beginning at 8PM EST with the heated Tigres vs. América Liga MX rivalry match. Source: Nielsen National TV View, National Sample; Panel Only, TV with Digital. Live+Same Day, Strict Daypart Averages Mon-Sun 7p-11p; P18-49 AA (units). Season-to-date (9/23/24-7/27/25), July 2025 (6/30/25-7/27/25); July 2024 (7/01/24-7/28/24). ABOUT MEDIACO MediaCo Holding Inc. (Nasdaq: MDIA) is a diverse-owned, multi-platform media company serving multicultural audiences across the U.S. Through its influential brands—including Hot 97, WBLS, EstrellaTV, Estrella News, Que Buena Los Angeles, and the Don Cheto Radio Network—MediaCo reaches over 20 million people monthly via television, radio, digital, and streaming platforms. Its content spans music, news, and entertainment across major local and national markets. Learn more at
Yahoo
an hour ago
- Yahoo
Ryvyl Second Quarter 2025 Earnings: US$0.36 loss per share (vs US$1.88 loss in 2Q 2024)
Ryvyl (NASDAQ:RVYL) Second Quarter 2025 Results Key Financial Results Revenue: US$2.78m (down 77% from 2Q 2024). Net loss: US$3.84m (loss narrowed by 68% from 2Q 2024). US$0.36 loss per share (improved from US$1.88 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Ryvyl shares are down 5.8% from a week ago. Risk Analysis Before we wrap up, we've discovered 5 warning signs for Ryvyl (4 can't be ignored!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
